Organon & Co.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OGN research report →
Companywww.organon.com
Organon & Co. , a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
- CEO
- Joseph T. Morrissey Jr.
- IPO
- 2021
- Employees
- 10,000
- HQ
- Jersey City, NJ, US
Price Chart
Valuation
- Market Cap
- $3.53B
- P/E
- 14.25
- P/S
- 0.57
- P/B
- 3.88
- EV/EBITDA
- 8.29
- Div Yield
- 0.59%
Profitability
- Gross Margin
- 53.11%
- Op Margin
- 19.23%
- Net Margin
- 3.99%
- ROE
- 29.87%
- ROIC
- 5.16%
Growth & Income
- Revenue
- $6.22B · -2.92%
- Net Income
- $187.00M · -78.36%
- EPS
- $0.72 · -78.57%
- Op Income
- $1.28B
- FCF YoY
- -8.50%
Performance & Tape
- 52W High
- $13.48
- 52W Low
- $5.69
- 50D MA
- $9.28
- 200D MA
- $8.66
- Beta
- 1.55
- Avg Volume
- 8.98M
Get TickerSpark's AI analysis on OGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 6, 26 | Holzbaur Lynette | other | 45.939 |
| May 6, 26 | Holzbaur Lynette | sell | 26,448.366 |
| May 6, 26 | Holzbaur Lynette | buy | 26,448.366 |
| Mar 31, 26 | Drinane Juliana Papa | other | 125,208 |
| Mar 31, 26 | Drinane Juliana Papa | other | 10,073 |
| Mar 31, 26 | Drinane Juliana Papa | other | 3,451 |
| Mar 31, 26 | Drinane Juliana Papa | other | 6,378 |
| Mar 31, 26 | Drinane Juliana Papa | other | 2,185 |
| Mar 31, 26 | Drinane Juliana Papa | other | 10,073 |
| Mar 31, 26 | Drinane Juliana Papa | other | 6,378 |
Our OGN Coverage
We haven't published any research on OGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OGN Report →